OBI Pharma’s Subsidiary OBIGEN Pharma Reports Positive Phase II Trial Results for Next-Generation Botulinum Toxin; Plans Taiwan Emerging Stock Board Listing by Year-End

OBIGEN Pharma, a subsidiary of Taiwan-based OBI Pharma, announced on the 26th that its independently developed next-generation botulinum toxin, OBI-858, has successfully met the primary efficacy endpoint with statistical significance in its first human Phase II clinical trial (OBI-858-002). Two pivotal Phase III trials for OBI-858 have recently been approved by the Taiwan Food and Drug Administration (TFDA). To support international expansion, OBIGEN plans to launch a cash capital increase in the fourth quarter of this year and aims to apply for listing on Taiwan’s Emerging Stock Board before year-end.